Screener
4D Molecular Therapeutics FDMT Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from 4D Molecular Therapeutics’s reported figures.
Based on the most recent quarter.
The source filing: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211939
FAQ
- What is 4D Molecular Therapeutics's debt-to-equity?
- 4D Molecular Therapeutics (FDMT) reported debt-to-equity of 0× in Q1 2026.
- How has 4D Molecular Therapeutics's debt-to-equity changed year-over-year?
- 4D Molecular Therapeutics's debt-to-equity decreased by 10.6% year-over-year, from 0.1× to 0×.
- What is the long-term trend for 4D Molecular Therapeutics's debt-to-equity?
- Over 5 years (2020 to 2025), 4D Molecular Therapeutics's debt-to-equity has grown at a -9.7% compound annual growth rate (CAGR), from 0.1× to 0×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about 4D Molecular Therapeutics's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude